Hematopoietic growth factor levels in term and preterm infants

Current Opinion in Hematology

Volumn 6, Issue 3, 1999, Pages 192-197

  Rondini, Giorgio ^a   Chirico, Gaetano ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOPOIETIC GROWTH FACTOR;

ADAPTATION; ARTICLE; CELL PROLIFERATION; COMPLEX FORMATION; CYTOKINE RELEASE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LOW BIRTH WEIGHT; POSTNATAL DEVELOPMENT; PREMATURITY; PRIORITY JOURNAL; UMBILICAL CORD BLOOD;

GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC CELL GROWTH FACTORS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE;

EID: 0032868984     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199905000-00011     Document Type: Article

References (59)

1. 1 Chalmers IM, Janossy G, Contreras M, Navarrete C: Intracellular cytokine profile of cord and adult blood lymphocytes. Blood 1998, 92:11-18. The cytokine profile of cord blood lymphocytes assessed at the single-cell level showed a reduced production of IL-2, IL-4, IFN-gamma, and TNF-α, as compared to adult peripheral blood lymphocytes. The authors suggest that the reduced incidence of acute graft-versus-host disease in cord blood transplantation may partly due to the altered cytokine profile seen in cord blood.
2. 2 Sautois B, Fillet G, Beguin Y: Comparative cytokine production by in vitro stimulated mononucleated cells from cord blood and adult blood. Exp Hematol 1997, 25:103-108. A comparison of cord blood and adult blood cytokine production by stimulated mononuclear cells showed a reduced production of IFN-gamma, TNF-α, and IL-4 by cord blood cells. The authors suggest that the cytokine production pattern that characterizes cord blood could provide an explanation for the lower occurrence of acute graft-versus-host disease following cord blood transplant.
3. 3 Wilson CB, Lewis DB, Penic LA: The physiologic immunodeficiency of immaturity. In Immunologic Disorders in Infants and Children, edn 4. Edited by Stiehm ER. Philadelphia: WB Saunders; 1996:253-295.
4. 4 Goldman S, Ellis R, Dhar V, Cairo MS: Rationale and potential use of cytokines in the prevention and treatment of neonatal sepsis. Clin Perinatol 1998, 25:699-709.
5. 5 Chirico G, Ciardelli L, Cecchi P, De Amici M, Gasparoni A, Rondini G: Serum concentration of granulocyte colony stimulating factor (G-CSF) in term and preterm infants. Eur J Pediatr 1997, 156:269-271.
6. 6 Cairo MS: Therapeutic implications of dysregulated colony-stimulating factor expression in neonates. Blood 1993, 82:2269-2272.
7. 7 Bedford Russel AR, Graham Davies E, Ball SE, Gordon-Smith E: Granulocyte colony stimulating factor treatment for neonatal neutropenia. Arch Dis Child 1995, 72:F53-F54.
8. 8 Kennon C, Overturf G, Bessman S, Sierra E, Smith KJ, Brann B: Granulocyte colony stimulating factor as a marker for bacterial infection in neonates. J Pediatr 1996, 128:765-769.
9. 9 Gessler P, Kirchmann N, Kientsch-Engel R, Haas N, Lasch P, Kachel W: Serum concentrations of granulocyte colony stimulating factor in healthy term and preterm neonates and in those with various diseases including bacterial infections. Blood 1993, 82:3177-3182.
10. 10 Laver J, Duncan E, Abboud M, Gasparetto C, Sahdev I, Warren D, et al.: High levels of granulocyte and granulocyte-macrophage colony-stimulating factors in cord blood of normal full-term neonates. J Pediatr 1990, 116:627-631.
11. 11 Wilimas JA, Wall JE, Fairclough DL, Dancy R, Griffin C, Karanth S, et al.: A longitudinal study of granulocyte colony-stimulating factor levels and neutrophil counts in newborn infants. J Pediatr Hematol Oncol 1995, 17:176-179.
12. 12 Calhoun DA, Christensen RD: A randomized pilot trial of administration of granulocyte colony-stimulating factor to women before preterm delivery. Am J Obstet Gynecol 1998, 179:766-771.
13. 13 Chirico G, Ciardelli L, Gasparoni A, Viganò C, Rondini G: Clinical and experimental aspects on the use of granulocyte colony stimulating factor (G-CSF) in the neonate. In Neonatal Hematology and Immunology III. Edited by Bellanti JA, Bracci R, Prindull G, Xanthou M. Amsterdam: Elsevier Science; 1997:33-38.
14. 14 Weimann E, Rutkowski S, Reisbach G: G-CSF, GM-CSF and IL-6 levels in cord blood: diminished increase of G-CSF and IL-6 in preterms with perinatal infection compared to term neonates. J Perinat Med 1998, 26:211-218.
15. 15 Bailie KEM, Irvine AE, Bridges JM, McClure BG: Granulocyte and granulocyte-macrophage colony-stimulating factors in cord and maternal serum at delivery. Pediatr Res 1994, 35:164-168.
16. 16 Kocherlakota P, La Gamma EF: Preliminary report: rhG-CSF may reduce the incidence of neonatal sepsis in prolonged preeclampsia-associated neutropenia. Pediatrics 1998, 102:1107-1111.
17. 17 Makhlouf RA, Doron MW, Bose CL, Price WA, Stiles AD: Administration of granulocyte colony-stimulating factor to neutropenic low birth weight infants of mothers with preeclampsia. J Pediatr 1995, 126:454-456.
18. 18 Kocherlakota P, La Gamma EF: Human granulocyte-colony stimulating factor may improve outcome attributable to neonatal sepsis complicated by neutropenia. Available electronically. Pediatrics 1997, 100:E6.
19. 19 Gillan ER, Christensen RD, Suen Y, Ellis R, van de Ven C, Cairo MS: A randomized, placebo-controlled trial of recombinant human granulocyte colony-stimulating factor administration in newborn infants with presumed sepsis: significant induction of peripheral and bone marrow neutrophilia. Blood 1994, 84:1427-1433.
20. 20 min Lee S, Knoppel E, van de Ven C, Cairo MS: Transcriptional rates of granulocyte-macrophage colony-stimulating factor, granulocyte colony-stimulating factor, interleukin-3, and macrophage colony-stimulating factor genes in activated cord versus adult mononuclear cells: alteration in cytokine expression may be secondary to posttranscriptional instability. Pediatr Res 1993, 34:560-564.
21. 21 English BK, Hammond WP, Lewis DB, Brown CB, Wilson CB: Decreased granulocyte-macrophage colony-stimulating factor production by human neonatal blood mononuclear cells and T cells. Pediatr Res 1992, 31:211-216.
22. 22 Buonocore G, De Filippo M, Gioia D, Picciolini E, Luzzi E, Bocci V, Bracci R: Maternal and neonatal plasma cytokine levels in relation to mode of delivery. Biol Neonate 1995, 68:104-110.
23. 23 Garofalo RP, Goldman AS: Cytokines, chemokines, and colony-stimulating factors in human milk: the 1997 update. Biol Neonate 1998, 74:134-142.
24. 24 Doyle JJ: The role of erythropoietin in the anemia of prematurity. Semin Perinatol 1997, 21:20-27.
25. 25 Strauss RG: Recombinant erythropoietin for the anemia of prematurity: still a promise, not a panacea. J Pediatr 1997, 131:653-655.
26. 26 Ohls RK, Harcum J, Li Y, Davila G, Christensen RD: Serum erythropoietin concentrations fail to increase after significant phlebotomy losses in ill preterm infants. J Perinatol 1997, 17:465-467.
27. 27 Jazayeri A, Tsibris JC, Spellacy WN: Umbilical cord plasma erythropoietin levels in pregnancies complicated by maternal smoking. Am J Obstet Gynecol 1998, 178:433-435.
28. 28 Fang S, Sherwood RA, Gamsu HR, Mardsen JT, Peters JT, Greenough A: Comparison of the effects of theophylline and caffeine on serum erythropoietin concentration in premature infants. Eur J Pediatr 1998, 157:406-409.
29. 29 Mayer RF, Obladen M, Kattner E, Natzschka J, Messer J, Regazzoni BM, et al.: High- versus low-dose erythropoietin in extremely low birth weight infants. J Pediatr 1998, 132:866-870. In this large European multicenter trial involving 184 extremely low birth weight infants, the authors found a similar response rate in the low-dose and high-dose groups and concluded that doubling the erythropoietin dose from 750 to 1500 IU/kg/wk is not indicated in infants with birth weights of less than 1000 g.
30. 30 Griffiths G, Lall R, Chatfield S, Short A, Mackay P, Williamson P, et al.: Randomised controlled double blind study of role of recombinant erythropoietin in the prevention of chronic lung disease. Arch Dis Child 1997, 76:F190-F192.
31. 31 Atici A, Satar M, Alparsalan N: Serum interleukin-1b in neonatal sepsis. Acta Paediatr 1996, 85:371-374.
32. 32 Berner R, Niemeyer CM, Leititis JU, Funke A, Schwab C, Rau U, et al.: Plasma levels and gene expression of granulocyte colony-stimulating factor, tumor necrosis factor-α, interleukin (IL)-1β, IL-6, IL-8, and soluble intercellular adhesion molecule-1 in neonatal early onset sepsis. Pediatr Res 1998, 44:469-477. An evaluation of cytokine plasma levels and gene expression in healthy neonates and in infants with clinically suspected or confirmed sepsis is presented in this paper. The results suggest that cord plasma levels of G-CSF, tumor necrosis factor-α, interleukin-1β, interleukin-6, and interleukin-8 can predict early-onset neonatal sepsis with high sensitivity and specificity.
33. 33 de Bont ESJM, Martens A, van Raan J, Samson G, Fetter WPF, Okken A, Leij LHFM: Tumor necrosis factor-a, interleukin-1b, and interleukin-6 plasma levels in neonatal sepsis. Pediatr Res 1993, 33:380-383.
34. 34 Miller LC, Isa S, LoPreste G, Schaller JG, Dinarello CA: Neonatal interleukin-1b, interleukin-6, and tumor necrosis factor: cord blood levels and cellular production. J Pediatr 1990, 117:961-965.
35. 35 Ng PC, Cheng SH, Chui KM, Fok TF, Wong MY, Wong W, et al.: Diagnosis of late onset neonatal sepsis with cytokines, adhesion molecule, and C-reactive protein in preterm very low birthweight infants. Arch Dis Child 1997, 77:F221-F227.
36. 36 Srugo I, Berger A, Lapidot Z, Katz R, Pollak S: Interleukin-1 secretion by blood monocytes of septic premature infants. Infection 1991, 19:150-154.
37. 37 Oygür N, Sönmez O, Saka O, Yeǧin O: Predictive value of plasma and cerebrospinal fluid tumour necrosis factor-a and interleukin-1b concentrations on outcome of full term infants with hypoxic-ischaemic encephalopathy. Arch Dis Child 1998, 79:F190-F193.
38. 38 Küster H, Weiss M, Willeitner AE, Detlefsen S, Jeremias I, Zbojan J, et al.: Interleukin-1 receptor antagonist and interleukin-6 for early diagnosis of neonatal sepsis 2 days before clinical manifestation. Lancet 1998, 352:1271-1277. In this multicenter study, significant elevations of interleukin-1 receptor antagonist and interleukin-6 concentration were observed 1 or more days before the onset of clinical signs of neonatal sepsis. The authors conclude that ad hoc measurement of these cytokines could allow earlier initiation of therapy with corresponding improvement in outcome of infants with sepsis.
39. 39 Tang ML, Kemp AS: Ontogeny of IL4 production. Pediatr Allergy Immunol 1995, 6:11-19.
40. 40 Doeller H, Arntzen KJ, Haereid PE, Aag S, Austgulen R: Interleukin-6 concentrations in neonates evaluated for sepsis. J Pediatr 1998, 132:295-299.
41. 41 Panero A, Pacifico L, Rossi N, Mancuso G, Stegagno M, Chiesa C: Interleukin-6 in neonates with early and late onset infection. Pediatr Infect Dis J 1997, 16:370-375.
42. 42 Seghaye MC, Heyl W, Grabitz RG, Schumacher K, Bernuth von G, Ruth W, Duchateau J: The production of pro- and anti-inflammatory cytokines in neonates assessed by stimulated whole cord blood culture and by plasma levels at birth. Biol Neonate 1998, 73:220-227.
43. 43 Chheda S, Palkowetz KH, Garofalo R, Rassin DK, Goldman AS: Decreased interleukin-10 production by neonatal monocytes and T cells: relationship to the decreased production and expression of tumor necrosis factor-a and its receptors. Pediatr Res 1996, 40:475-483.
44. 44 Scott ME, Kubin M, Kohl S: High level interleukin-12 production, but diminished interferon-g production, by cord blood mononuclear cells. Pediatr Res 1997, 41:547-553.
45. 45 Suen Y, min Lee S, Qian J, van de Ven C, Cairo MS: Dysregulation of lymphokine production in the neonate and its impact on neonatal cell mediated immunity. Vaccine 1998, 16:1369-1377. This review of cord blood cytokine production and function is reported by investigators who have contributed much to the knowledge of neonatal hematopoiesis and immune function over the past decade. It discusses the mechanisms associated with the dysregulation of GM-CSF, M-CSF, interleukin-12, and interleukin-15; the effect of these cytokines on induction of interferon gamma and tumor necrosis factor-α production; and their effect on natural killer cell and lymphokine-activated killer cell activities in cord blood. The authors conclude that the reduced cytokine expression from activated cord blood may contribute to the impaired neonatal cellular immunity and suggest that exogenous cytokines may compensate for the immaturity of cord blood cells.
46. 46 Qian JX, Lee YS, Knoppel E, Ven van de C, Cairo MS: Decreased interleukin-15 from activated cord versus adult peripheral blood mononuclear cells and the effect of interleukin-15 in upregulating antitumor immune activity and cytokine production in cord blood. Blood 1997, 90:3106-3117.
47. 47 Atici A, Satar M, Ĉetiner S, Yaman A: Serum tumor necrosis factor-alpha in neonatal sepsis. Am J Perinatol 1997, 14:401-404.
48. 48 Girardin EP, Berner ME, Grau GE, Suter S, Lacourt G, Paunier L: Serum tumor necrosis factor in newborns at risk for infections. Eur J Pediatr 1990, 149:645-647.
49. 49 Bessler H, Kuperman A, Beilin B, Klinger G, Gurary N, Mozes C, Sirota L: Labor affects cytokine production in newborns. Am J Reprod Immunol 1998, 39:27-32.
50. 50 Phocas I, Sarandakou G, Giannaki G, Malamitsi-Puchner A, Rizos D, Zoudas PA: Soluble intercellular adhesion molecule-1 in newborn infants. Eur J Pediatr 1998, 157:153-156.
51. 51 Messer J, Eyer D, Donato L, Gallati H, Matis J, Simeoni U: Evaluation of interleukin-6 and soluble receptors of tumor necrosis factor for early diagnosis of neonatal infection. J Pediatr 1996, 129:574-580.
52. 52 Schibler KR, Liechty KW, White WL, Christensen RD: Production of granulocyte colony-stimulating factor in vitro by monocytes from preterm and term neonates. Blood 1993, 82:2478-2484.
53. 53 Savas A, Ince S, Coskun M, Durmaz S, Yogin O: Stem cell factor (SCF) levels in newborns. Am J Perinatol 1998, 15:427-429.
54. 54 Murray NA, Watts TL, Roberts IA: Endogenous thrombopoietin levels and effect of recombinant human thrombopoietin on megakaryocyte precursors in term and preterm babies. Pediatr Res 1998, 43:148-151. This is the first comprehensive report on plasma thrombopoietin levels in newborn infants. Although no significant differences were found between normal term and preterm infants, no response to thrombocytopenia was observed in preterm infants, suggesting that impaired fetal thrombopoietin production may be a factor in early thrombocytopenia in preterm infants.
55. 55 Barak Y, Leibovitz E, Mogilner B, Juster-Reicher A, Amitay M, Ballin A, et al.: The in vivo effect of recombinant human granulocyte-colony stimulating factor in neutropenic neonates with sepsis. Eur J Pediatr 1997, 156:643-646.
56. 56 Drossou-Agakidou V, Kanakoudi-Tsakalidou F, Sarafidis K, Taparkou A, Tzimouli V, Tsandati H, Kremenopoulos G: Administration of recombinant human granulocyte-colony stimulating factor to septic neonates induces neutrophilia and enhances the neutrophil respiratory burst and b2 integrin expression: results of a randomized controlled trial. Eur J Pediatr 1998, 157:583-588.
57. 57 Schibler KR, Osborne KA, Leung LY, Le TV, Baker SI, Thompson DD: A randomized, placebo-controlled trial of granulocyte colony-stimulating factor administration to newborn infants with neutropenia and clinical signs of early-onset sepsis. Pediatrics 1998, 102:6-13.
58. 58 Cairo MS, Christensen R, Sender LS, Ellis R, Rosenthal J, van de Ven C, et al.: Results of a phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in very low birthweight neonates: significant induction of circulatory neutrophils, monocytes, platelets, and bone marrow neutrophils. Blood 1995, 86:2509-2515.
59. 59 Cairo MS, Seth T, Fanaroff A, Puppala B, DeLemos R, Givner L, et al.: A double-blinded, randomized, placebo controlled pilot study of RhGM-CSF in low birth weight neonates: preliminary results demonstrate a significant reduction in nosocomial infections with RhuGM-CSF [abstract]. Pediatr Res 1996, 39:294a.